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Systems medicine is an interdisciplinary approach that
integrates data from basic research and clinical practice
to improve our understanding and treatment of diseases.
Systems medicine can be seen as a further development
of systems biology and bioinformatics towards applica-
tions of clinical relevance. The term 'systems' refers to
systems approaches, emphasizing a close integration of
data generation with mathematical modeling [1-3]. The
(mal)functioning of the human body is a complex process,
characterized by multiple interactions between systems
that act across multiple levels of structural and functional
organization - from molecular reactions to cell-cell interac-
tions in tissues to the physiology of organs and organ
systems. Over the past decade, we have gained detailed
insights into the structure and function of molecular, cellu-
lar and organ-level systems, with technologies playing an
important role in the generation of data at these different
scales.
Under the umbrella of systems biology, workflows of
data-driven modeling and model-driven experimentation
have led to the development of computational models that
describe processes at all levels, including gene regulatory
networks, signal transduction pathways and metabolic
networks, cell populations, structured tissues, pharmaco-
kinetic and pharmacodynamic models that analyze drug
or vaccine action at the whole organism level, and phar-
macogenomic models of disease risk and drug and vaccine
exposure at the patient-population level.
Major challenges exist for the development of quanti-
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macokinetic and pharmacodynamic models. One hurdle
is the technical difficulty associated with generating
sufficiently comprehensive quantitative datasets for large
numbers of system variables, across different levels of
organization. Another major challenge is the develop-
ment of efficient tools that can handle the wide variety
of available data and identify relevant data subsets from
existing repositories. Overcoming these hurdles will lead
to the development of models that can be used in
clinical practice while accounting for the uncertainty in
the data.
Another important challenge for systems medicine is
the integration of this knowledge across the relevant
levels of organization. Large, long-term research initia-
tives, like the Virtual Physiological Human, the Virtual
Liver or the Human Brain Project, are aiming to develop
comprehensive, computational representations of organs
and organ systems. Here, we focus on opportunities for
comparatively small interdisciplinary collaborations be-
tween clinicians and modelers who are targeting specific
questions of clinical relevance. In the projects that we
envisage, modeling is not the final goal; rather, it is a tool
that can be used to advance understanding of the system,
to develop more directed experiments in the laboratory
and, ultimately, to generate testable predictions to enable
improved therapies and prophylaxes.Multiscale modeling
The fields of theoretical and mathematical biology have
pioneered the development of mathematical and compu-
tational models of biological systems. Systems biology
has contributed workflows for data-driven modeling and
model-driven experimentation to the life sciences. Taken
together, these provide a considerable body of experi-
ence for modeling at different levels (Box 1).entral Ltd. The licensee has exclusive rights to distribute this article, in any
cation. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Molecular modeling, for example
•Drug/vaccine target interactions
•Prediction of pathogenic mutations
•Protein-protein interactions
Modeling of subcellular processes, for example:
•Signaling pathways, gene regulatory networks, metabolic
networks
•Drug target prediction by sensitivity analysis
•Linking signaling pathways to phenotypic changes (for example,
regression models)
Individual-cell or cell-based models, for example:
•Behavior of individual cells in their microenvironment
•Cell-cell interactions
•Control of cell material properties and shape by molecular
mechanisms, and the effect of physical properties of cells and
their environment on cell decisions
Tissue/organ level models, for example:
•Population dynamics, the formation and maintenance of tissue
architecture
•Cell-stroma interactions, for example epithelial-mesenchymal
transition
•Mechanobiology/biomechanical models
Body systems level models, for example:
•Pharmacokinetic/pharmacodynamic modeling
•Physiologically based pharmacokinetic modeling for applications
in systems pharmacology
•Modeling environmental influences and long-term clinical events
(for example, overall survival).
Box 1. Different levels at which modeling of biological
systems has been carried out
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indicate the progression of modeling efforts, with an in-
creasing diversity of approaches available, a tendency to
combine approaches in modeling workflows, and clear
indications of an increasing number of successful case
studies.
Multiscale modeling serves as a ‘macroscope’ that inte-
grates the evidence available at different levels of a par-
ticular system’s structural and functional organization
while enabling us to zoom in on the details where neces-
sary. For experimental models, it is almost certain that
not all parameters influencing a disease will be known
and, often, known parameters cannot be influenced and/
or measured. This makes it difficult to unambiguously
identify the mechanisms at work in diseases. Modeling
therefore makes an epistemic contribution by allowing in
silico (simulation) experiments under defined conditions,aiding the exploration of hypotheses by explicitly ac-
counting for the uncertainty that arises from biological
complexity.
Central to these efforts are data of high quality that
are quantitative, derived from reproducible studies and
that cover multiple levels of functional and structural
organization, generated from a range of experimental
systems. A particularly important challenge is to enable
clinical validation of models and simulations.
Actions required for multiscale modeling
Our discussions have identified a number of
recommendations.
Short-term recommended actions
With respect to data collection and modeling, in the
short-term (that is, the next one to two years), the fol-
lowing actions should be given priority:
1. Exploitation of existing data as a starting point for
multiscale modeling. This will lead to the
identification of gaps in data and, therefore, in
understanding of underlying mechanisms, and will
improve the targeted generation of new data that
can be exploited for quantitative models.
2. Development of standard operating procedures and
quality standards for the systematic collection of
quantitative data and information. This will enable
models to be built and validated for specific
applications.
3. Definition of test scenarios and proof-of-concept
studies.
4. Identification of required standards and ontologies
(for example, a markup language and ontology for
individual-based models) for models and data reposi-
tories in systems medicine.
5. Development of concepts for dedicated modeling
workflows for the integration of data and models.
These research actions would benefit from initiatives
that coordinate training and encourage collaborations
between clinicians and multiscale modelers; support co-
ordinated clinical projects to bring clinicians, modelers
and biologists together; and run sandpits for modelers
and clinicians to develop proposals to address clinical
questions, to improve mutual understanding and provide
realistic expectations for such collaborations.
Medium-term recommended actions
In the medium-term of two to three years, attention
should focus on the provision of suitable information
technology infrastructure and the development of stan-
dards, such as:
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algorithms for efficient multiscale simulations.
2. The development of mathematical formalism to
analyze and compare multiscale models such as
parameter estimation, sensitivity analysis,
identifiability analysis and image analysis.
3. Support for the development of workflows for
modeling, including computational tools that
support data management, model construction and
analysis.
4. Methods to integrate different physical phenomena,
including those of mechanotransduction, electrical,
mechanical and chemical origin.
5. Methods to investigate the interplay between the
environment, cell behavior and cell fate.
In the medium term, the goal is to develop multiscale
models of normal physiology and disease. The develop-
ment of these models should be driven by clinical ques-
tions to provide the basis for clinical validation in the
longer term. This will require technologies that promote
and facilitate the collaboration of multidisciplinary
teams.
Longer-term recommended actions
On a timescale beyond four years, the focus should be
on the application and validation of multiscale models in
the clinic. To this end, it is desirable to:
1. Enhance the formation of small-scale networks
focused on specific clinical needs, possibly clustered
in a larger integrated project (longer timescale).
2. Have a funding model in place for small groups of
two to three partners (one to two modeling
postdocs, one to two experimental postdocs plus
consumables and travel between laboratories). Such
a funding model has been applied in systems biology
to good effect, with smaller groups being integrated
through networks.
The main priority for systems medicine is the develop-
ment of computational models that integrate data and
knowledge from the clinics and basic science (in vitro
and animal model experiments) and are applicable to
individual patients. The aim is to derive a mechanistic
understanding of pathologies, prophylaxy and support of
therapy optimization. This requires the development of
concepts, methods and tools that support the integration
of organizational levels to develop interfaces between
the computational and mathematical frameworks used
in systems medicine.
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